These findings suggest that patients with EGFR + NSCLC have a distinct gut microbiota profile relative to patients with EGFR- NSCLC, and our findings provide a basis for future advances in live bacterial therapeutics. This evidence concerns the gene EGFR and non-small cell lung carcinoma.